banner
JNK-c-Jun inhibitor JNK-IN-8, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ927

JNK-c-Jun inhibitor JNK-IN-8, Purity ≥98%

Synonym: JNK-IN-8; 1410880-22-6; JNK Inhibitor XVI; JNK-IN-8 (GMP); 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; (E)-3-(4-(dimethylamino)but-2-enamido)-N-(3-methyl-4-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide; 1644498-56-5; JNK-c-Jun inhibitor

  • CAS Number: 1410880-22-6
  • Compound CID: 57340686
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
JNK-IN-8, soluble in warmed DMSO and insoluble in water and ethanol, is an inhibitor of c-jun N-terminal kinase (JNK) signaling.
Molecular Weight
507.59
Molecular Formula
C29H29N7O2
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 91 mg/mL (179.27 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
JNK-IN-8 is applied as a tool for the selective inhibition of JNK and its role in inflammatory and apoptotic pathways.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0